ArticleNature
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia.
Article in Nature. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 274 citations in OpenAlex.
- Trial
- Moving Beyond the Plateau in Immune Checkpoint Inhibition-The Imperative of Early Referral and Precision Strategies.Journal of immunotherapy and precision oncology · 2026Article
- Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategies.Seminars in cancer biology · 2025Review
- Ag(e)nostic precision oncology therapy approvals across the years.Trends in cancer · 2025Review
- Tumour-agnostic kinase inhibitors.Nature reviews. Drug discovery · 2025Review
- If it is a solid tumor target, then it may be a hematologic cancer target: Bridging the great divide.Med (New York, N.Y.) · 2025Review
- An updated account on molecular heterogeneity of acute leukemia.American journal of blood research · 2021Review
- Review of precision cancer medicine: Evolution of the treatment paradigm.Cancer treatment reviews · 2020Review
- Article
- Insights into the prenatal origin of childhood acute lymphoblastic leukemia.Cancer metastasis reviews · 2020Review
- A rare e14a3 BCR/ABL fusion transcript in acute lymphoblastic leukemia patient treated with CAR-modified T-cell therapy.Oncology letters · 2018Article
- The Conundrum of Genetic "Drivers" in Benign Conditions.Journal of the National Cancer Institute · 2016Review
- Bosutinib for the Treatment of Philadelphia Chromosome-Positive Leukemias.Expert opinion on orphan drugs · 2015Article
- Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development.British journal of haematology · 2010Review
- Molecular imaging of Bcr-Abl phosphokinase in a xenograft model.Molecular cancer therapeutics · 2009Article
- Article
- Review
- Article
- Article
- Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activation of cellular proto-oncogenes as a result of chromosomal abnormalities has been implicated in the development of some human malignancies. Perhaps one of the most striking examples of this association occurs in chronic myelogenous leukaemia, where the Philadelphia (Ph) translocation results in substitution of the 5' end of the c-abl proto-oncogene with bcr gene sequences. A unique hybrid bcr-abl message is produced. As the Ph translocation is also present in some patients with acute lymphoblastic leukaemia, we initiated studies to determine if similar genomic events occur in these two different forms of Ph-positive leukaemia. Here we report that the Ph translocation in acute lymphoblastic leukaemia can result in production of a novel aberrant c-abl protein that is distinct from the bcr-abl protein found in Ph-positive chronic myelogenous leukaemia. Our observations suggest that alternative mechanisms of activation of c-abl exist, and may be important in the development of human acute lymphoid rather than chronic myeloid malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.